A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells

A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells

Ovarian cancer cells overexpress HDAC6, and selective HDAC6 inhibitors have been considered potential new drugs for ovarian cancer either alone or in combination with other anticancer agents. We screened 46 potential novel HDAC6 inhibitors in ES-2 ovarian cancer cells and showed that compound <b&...

Full description

Saved in:
Bibliographic Details
Main Authors: An-Jui Chi, Jui-Ling Hsu, Yun-Xin Xiao, Ji-Wang Chern, Jih-Hwa Guh, Chao-Wu Yu, Lih-Ching Hsu
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Molecules
Subjects:
HDAC6 inhibitor
paclitaxel (Taxol)
ovarian cancer
combination therapy
apoptosis
Online Access:https://www.mdpi.com/1420-3049/30/13/2793
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1420-3049/30/13/2793

Similar Items